Identifying advanced stage NSCLC patients who benefit from afatinib therapy using 18F-afatinib PET/CT imaging
نویسندگان
چکیده
ObjectivesNon-small cell lung cancer (NSCLC) tumors harboring common (exon19del, L858R) and uncommon (e.g. G719X, L861Q) activating epidermal growth factor receptor (EGFR) mutations are best treated with EGFR tyrosine kinase inhibitors (TKI) such as the first-generation TKI erlotinib, second-generation afatinib or third-generation osimertinib. However, identifying these patients through biopsy is not always possible. Therefore, our aim was to evaluate whether 18F-afatinib PET/CT could identify mutations. Furthermore, we evaluated relation between tumor uptake response therapy.Materials methods18F-afatinib performed in 12 patients: 6 wild type (WT), 3 Tumor of quantified using TBR_WB60−90 (tumor-to-whole blood activity ratio 60−90 min post-injection) for each tumor. Response per lesion percentage change (PC): [(response measurement (RM)–baseline (BM))/BM]×100. Statistical analyses were t-tests, correlation plots sensitivity/specificity analysis.ResultsTwenty-one identified. Injected dose 348 ± 31 MBq. Group differences significant WT versus (common uncommon) (p = 0.03). There no difference 0.94). A cut-off value showed relationship a sensitivity 70 %, specificity 100 % positive predictive %.Conclusion18F-afatinib higher compared WT. found predict therapy. provide means mutation who benefit from
منابع مشابه
Afatinib in advanced NSCLC: a profile of its use
Afatinib [Giotrif® (EU); Gilotrif® (USA)] is an orally administered, irreversible inhibitor of the ErbB family of tyrosine kinases that provides an important first-line treatment option for advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations (i.e. EGFRactMUT+), and an additional treatment option for squamous NSCLC that has progressed fol...
متن کاملGefitinib and afatinib treatment in an advanced non-small cell lung cancer (NSCLC) patient undergoing hemodialysis.
Renal failure in cancer patients is not a rare clinical condition and often contraindicates anticancer drug treatment; moreover, chemotherapeutic drugs are frequently identified as possible iatrogenic cause of renal failure. Molecular therapies, when appropriate, could represent a therapeutic option for cancer patients with severe renal disease, but the lack of knowledge in this field, at prese...
متن کاملAfatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC
The discovery of epidermal growth-factor receptor (EGFR)-activating mutations and the introduction of oral EGFR tyrosine kinase inhibitors (EGFR-TKIs) have expanded the treatment options for patients with non-small cell lung cancer. The first two reversible EGFR-TKIs, erlotinib and gefitinib, are approved for use in the first-line setting in patients with known EGFR-activating mutations and in ...
متن کاملCorrection to: Afatinib in advanced NSCLC: a profile of its use
The article ‘Afatinib in advanced NSCLC: a profile of its use’, written by Emma D. Deeks and Gillian M. Keating, was originally published Online First without open access. After Online First publication, Boehringer Ingelheim Pharmaceuticals, Inc. requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by Boehringer Ingelh...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Lung Cancer
سال: 2021
ISSN: ['1179-2728']
DOI: https://doi.org/10.1016/j.lungcan.2021.03.016